Chronic obstructive pulmonary disease: an emerging comorbidity in HIV-infected patients in the HAART era?

Infection. 2013 Apr;41(2):347-53. doi: 10.1007/s15010-012-0330-x. Epub 2012 Sep 13.

Abstract

Purpose: The objective of our study was to evaluate the presence of respiratory symptoms and chronic obstructive pulmonary disease (COPD) in a human immunodeficiency virus (HIV)-infected outpatient population and to further investigate the role of highly active antiretroviral therapy (HAART) and other possibly associated risk factors.

Methods: We consecutively enrolled in a cross-sectional study HIV-infected patients and HIV-negative age, sex and smoking status matched controls. All participants completed a questionnaire for pulmonary symptoms and underwent a complete spirometry.

Results: We enrolled 111 HIV-infected patients and 65 HIV-negative age- and sex-matched controls. HIV-infected patients had a significantly higher prevalence of any respiratory symptom (p = 0.002), cough (p = 0.006) and dyspnoea (p = 0.02). HIV-infected patients also had a significantly higher prevalence of COPD in respect of HIV-negative controls (p = 0.008). Furthermore, HIV-infected individuals had significantly (p = 0.002) lower forced expiratory volume at one second (FEV1) and FEV1/forced vital capacity (FVC) ratio (Tiffeneau index) (p = 0.028), whereas the total lung capacity (TLC) was significantly higher (p = 0.018). In the multivariate analysis, significant predictors of respiratory symptoms were current smoking [adjusted odds ratio (AOR) 11.18; 95 % confidence interval (CI) 3.89-32.12] and previous bacterial pneumonia (AOR 4.41; 95 % CI 1.13-17.13), whereas the only significant predictor of COPD was current smoking (AOR 5.94; 95 % CI 1.77-19.96). HAART receipt was not associated with respiratory symptoms nor with COPD.

Conclusions: We evidenced a high prevalence of respiratory symptoms and COPD among HIV-infected patients. HIV infection, current cigarette smoking and previous bacterial pneumonia seem to play a significant role in the development of respiratory symptoms and COPD. Thus, our results suggest that the most at-risk HIV-infected patients should be screened for COPD to early identify those who may need specific treatment.

MeSH terms

  • Adult
  • Antiretroviral Therapy, Highly Active*
  • Case-Control Studies
  • Comorbidity
  • Confidence Intervals
  • Cross-Sectional Studies
  • Female
  • Forced Expiratory Volume
  • HIV Infections / drug therapy
  • HIV Infections / epidemiology*
  • HIV Protease Inhibitors / pharmacology
  • Humans
  • Lung / pathology
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Odds Ratio
  • Prevalence
  • Pulmonary Disease, Chronic Obstructive / epidemiology*
  • Pulmonary Disease, Chronic Obstructive / virology*
  • Risk Factors
  • Ritonavir / pharmacology
  • Smoking / adverse effects
  • Spirometry
  • Surveys and Questionnaires
  • Total Lung Capacity

Substances

  • HIV Protease Inhibitors
  • Ritonavir